Business
Mesoblast holds out hope for heart failure drug – Sydney Morning Herald
Shares in the stem cell treatment developer regained some ground after a horror end to 2020.
Shares in stem cell biotech Mesoblast jumped nearly 16 per cent after the company said it would pursue approval for its key heart failure drug in the US despite a clinical trial delivering mixed results.
On Monday the company told investors that additional data from the phase 3 trial of its Revascor product showed a “substantial and durable reductions in heart attacks, strokes and cardiac deaths” in patients with chronic heart failure.
Mesoblast shares bounced after a tough end to 2020, when shares…
-
General23 hours agoTasmanian boy left homeless due to child protection department’s ‘gross negligence’, family member says
-
Noosa News20 hours agoTownsville remembers Jennifer Board, four years on from tragic death
-
Business17 hours agoBell Potter names the best ASX tech stocks to buy in FY 2026
-
Business22 hours ago2 excellent ASX ETFs I think have great potential to beat the ASX 200